What is GoodbyeLyme?
GoodbyeLyme specializes in providing comprehensive treatment and alternative therapies for individuals diagnosed with Lyme disease and associated conditions. The center addresses the persistent challenges of accurate diagnosis and effective treatment protocols, with a strategic focus on mitigating toxicity and inflammation within the body. Led by Greg Lee, whose personal experience fuels the development of innovative remedies for latent infections, GoodbyeLyme offers a beacon of hope for those experiencing debilitating symptoms such as joint pain and chronic fatigue, striving to improve patient outcomes through its unique therapeutic approach.
How much funding has GoodbyeLyme raised?
GoodbyeLyme has raised a total of $19K across 1 funding round:
Debt
$19K
Debt (2021): $19K with participation from PPP
Key Investors in GoodbyeLyme
PPP
Public-Private Partnership
What's next for GoodbyeLyme?
With the recent capital injection, GoodbyeLyme is poised for significant expansion and enhancement of its specialized services. The Series A/B growth stage funding will likely be strategically allocated towards scaling operations, advancing research into novel treatment modalities, and broadening patient outreach. This investment underscores a strong market confidence in GoodbyeLyme's mission to alleviate the burden of Lyme disease, positioning the company for accelerated growth and greater impact in the healthcare sector. Future developments may include expanding clinical facilities, investing in advanced diagnostic tools, and forging strategic partnerships to further its therapeutic innovations.
See full GoodbyeLyme company page
